title: Terbutaline tocolysis and glucose intolerance.
abstract: OBJECTIVE
  To determine whether there is an increased incidence of glucose intolerance in association with chronic terbutaline therapy, administered either orally or as a continuous subcutaneous infusion.
  
  
  METHODS
  Sixty-nine women received terbutaline, orally (38 subjects) or as a continuous subcutaneous infusion (31 subjects). Their gestational diabetes screening results were compared to the results in 82 women not receiving beta-mimetic therapy.
  
  
  RESULTS
  Subjects receiving terbutaline had significantly higher mean glucose concentrations after the 1-hour 50-g glucose tolerance test (GTT) than did controls (P < .05, one-way analysis of variance with multiple comparisons). Among subjects receiving a continuous subcutaneous infusion of terbutaline, the incidence of abnormal 3-hour 100-g GTT results was higher than among controls (20 versus 4%; P = .023 by chi 2).
  
  
  CONCLUSIONS
  The incidence of GTT abnormalities is increased among women receiving terbutaline. We recommend surveillance of glucose tolerance among patients receiving terbutaline chronically, regardless of the route of administration.
authors: Department of Obstetrics, Gynecology, University of California, San Francisco.
authors: A C
authors: AC
authors: Regenstein
authors: J
authors: J
authors: Belluomini
authors: M
authors: M
authors: Katz
mesh_terms: D000284:Administration, Oral; D000328:Adult; D016640:Diabetes, Gestational / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D015994:Incidence; D007263:Infusions, Parenteral; D011247:Pregnancy; D013726:Terbutaline / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015145:Tocolysis
chemical_list: D013726:Terbutaline